deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01292798

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab (REEF)

Open Label, Phase I/II, Residual Edema Evaluation With 0.5mg and 2.0mg Ranibizumab Formulations (REEF)

Sponsor: California Retina Consultants

Conditions Diabetic Macular Edema
Interventions Ranibizumab
Updated 8 times since 2017 Last updated: Mar 23, 2016 Started: Mar 31, 2011 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01292798, this PHASE1/PHASE2 trial focuses on Diabetic Macular Edema and remains completed. Sponsored by California Retina Consultants, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • California Retina Consultants
  • Genentech, Inc.
Data source: California Retina Consultants

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations